About Concord Drugs Limited
Data last updated: 23 December 2025
Concord Drugs Limited is a public limited company based in Na, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 24 April 1995, the company has been in operation for over 31 years.
Registered with ROC Hyderabad under CIN L24230TG1995PLC020093. Listed on BSE: 538965.
Capital: an authorised share capital of ₹15.5 Cr and a paid-up capital of ₹13.18 Cr. It is led by directors including Namratha and Nagi Reddy Seelam.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: Survey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India.
As per the financials filed for FY 2025, the company reported a revenue of ₹45.26 Cr, a growth of 1% compared to the previous year.
The company has a workforce of approximately 20 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Concord Drugs. As per MCA filings, the company has open charges of ₹18.25 Cr and satisfied charges of ₹7.4 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website concorddrugs.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressSurvey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Concord Drugs Limited
Concord Drugs Limited has one previous CIN (Corporate Identification Number): L24230AP1995PLC020093. The current CIN is L24230TG1995PLC020093, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230TG1995PLC020093 | Current |
| L24230AP1995PLC020093 | Previous |
Associated Brands with Concord Drugs Limited
Concord Drugs Limited operates one associated brand: Concord Drugs. These brands represent Concord Drugs Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of pharmaceutical formulations and ready-to-fill pellets | concorddrugs.in |
Business Activity of Concord Drugs Limited
Concord Drugs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Concord Drugs Limited
Concord Drugs Limited is audited by Pundarikashyam and associates (ICAI peer reviewed, certificate valid till 2017-10-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Pundarikashyam and associates (ICAI peer reviewed, certificate valid till 2017-10-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Concord Drugs Limited
Concord Drugs Limited is currently managed by 9 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Namratha
Also directs:
Concord Drugs Limited, Paysafecard.Com India Private Limited
|
Company Secretary | 19 Mar 2024 | 2 Years 3 Months | Current |
|
Nagi Reddy Seelam
Also directs:
Concord Drugs Limited, Cortex Laboratories Private Limited
|
Managing Director | 04 Apr 2003 | 23 Years 3 Months | Current |
|
Seelam Manojkumarreddy
Also directs:
Concord Drugs Limited, Cortex Laboratories Private Limited, Proton Remedies Private Limited and 1 more
|
Whole-Time Director | 13 Aug 2021 | 4 Years 10 Months | Current |
|
Ramchandra Reddy Kommula
Also directs:
Concord Drugs Limited
|
Director | 30 Mar 2019 | 7 Years 3 Months | Current |
|
Nagavenkatahareeshkumar Solleti
Also directs:
Concord Drugs Limited
|
Director | 13 Feb 2021 | 5 Years 4 Months | Current |
|
Sumeela Kasu
Also directs:
Concord Drugs Limited
|
Director | 01 Jun 2022 | 4 Years 1 Months | Current |
Financials of Concord Drugs Limited FY 2026 filings available
Concord Drugs Limited reported revenue of ₹78.74 Cr (up 74.02% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹78.74 Cr | ₹45.24 Cr | ₹44.92 Cr | ₹52.08 Cr |
| Other Income | ₹3.44 Lakh | ₹1.44 Lakh | ₹92,900 | ₹88,600 |
| Total Income | ₹78.77 Cr | ₹45.26 Cr | ₹44.93 Cr | ₹52.09 Cr |
| Cost of Materials Consumed | ₹68.03 Cr | ₹35.81 Cr | ₹33.66 Cr | ₹41.16 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹38.37 Lakh | -₹58.05 Lakh | -₹40.49 Lakh | -₹15.67 Lakh |
| Employee Benefit Expense | ₹4.97 Cr | ₹4.63 Cr | ₹6.08 Cr | ₹4.92 Cr |
| Finance Costs | ₹1.71 Cr | ₹2.03 Cr | ₹1.87 Cr | ₹1.71 Cr |
| Depreciation & Amortisation | ₹1.37 Cr | ₹1.43 Cr | ₹1.56 Cr | ₹1.63 Cr |
| Other Expenses | ₹1.6 Cr | ₹1.25 Cr | ₹1.55 Cr | ₹1.58 Cr |
| Total Expenses | ₹77.3 Cr | ₹44.57 Cr | ₹44.3 Cr | ₹50.84 Cr |
| Profit Before Exceptional Items & Tax | ₹1.47 Cr | ₹69.14 Lakh | ₹62.9 Lakh | ₹1.25 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1.47 Cr | ₹69.14 Lakh | ₹62.9 Lakh | ₹1.25 Cr |
| Total Tax Expense | ₹41.82 Lakh | ₹35.52 Lakh | ₹15.66 Lakh | ₹26.34 Lakh |
| Net Profit | ₹1.06 Cr | ₹33.62 Lakh | ₹47.24 Lakh | ₹98.55 Lakh |
| attributable to Owners | ₹1.06 Cr | - | ₹0 | ₹0 |
| attributable to NCI | ₹0 | - | ₹0 | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹1.06 Cr | ₹33.62 Lakh | ₹47.24 Lakh | ₹98.55 Lakh |
| EBITDA (computed) | ₹4.55 Cr | ₹4.15 Cr | ₹4.05 Cr | ₹4.58 Cr |
| Basic EPS | ₹0.95 | ₹0.34 | ₹0.47 | ₹1.06 |
| Diluted EPS | ₹0.95 | ₹0.34 | ₹0.47 | ₹1.06 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹74.89 Cr | ₹65.14 Cr | ₹58.81 Cr | ₹58.23 Cr |
| Non-current Assets | ₹21.58 Cr | ₹24.38 Cr | ₹14.19 Cr | ₹14.77 Cr |
| Current Assets | ₹53.31 Cr | ₹40.76 Cr | ₹44.62 Cr | ₹43.46 Cr |
| Property, Plant & Equipment | ₹10.94 Cr | ₹11.57 Cr | ₹11.04 Cr | ₹12.28 Cr |
| Inventories | ₹25.52 Cr | ₹25.27 Cr | ₹22.92 Cr | ₹20.06 Cr |
| Trade Receivables | ₹24.38 Cr | ₹13.6 Cr | ₹19.83 Cr | ₹15.81 Cr |
| Cash & Equivalents | ₹27.81 Lakh | ₹12.09 Lakh | ₹14.54 Lakh | ₹7.84 Lakh |
| Equity (Net Worth) | ₹48.51 Cr | ₹34.11 Cr | ₹33.82 Cr | ₹31.7 Cr |
| Equity Share Capital | ₹13.18 Cr | ₹10 Cr | ₹10 Cr | ₹9.32 Cr |
| Borrowings (Non-current) | ₹1.81 Cr | ₹1.32 Cr | ₹64.55 Lakh | ₹1.91 Cr |
| Borrowings (Current) | ₹11.79 Cr | ₹15.87 Cr | ₹15.95 Cr | ₹14.23 Cr |
| Total Debt (computed) | ₹13.6 Cr | ₹17.19 Cr | ₹16.59 Cr | ₹16.14 Cr |
| Current Liabilities | ₹21.07 Cr | ₹26.18 Cr | ₹21.34 Cr | ₹21.61 Cr |
| Total Liabilities | ₹26.37 Cr | ₹31.03 Cr | ₹24.99 Cr | ₹26.53 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -₹6.77 Cr | ₹3.72 Cr | ₹79.23 Lakh | ₹1.66 Cr |
| Investing Cash Flow | -₹1.13 Cr | -₹2.32 Cr | -₹1.01 Cr | -₹2.27 Cr |
| Financing Cash Flow | ₹8.06 Cr | -₹1.43 Cr | ₹28.34 Lakh | ₹62.4 Lakh |
| Capital Expenditure | ₹1.17 Cr | ₹2.33 Cr | ₹1.02 Cr | ₹85.66 Lakh |
| Free Cash Flow (computed) | -₹7.93 Cr | ₹1.39 Cr | -₹22.56 Lakh | ₹80.65 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹15.72 Lakh | -₹2.46 Lakh | ₹6.71 Lakh | ₹2.15 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹37.89 Cr | ₹16.97 Cr | ₹10.28 Cr | ₹13.61 Cr | ₹10.39 Cr | ₹10.8 Cr | ₹12.36 Cr | ₹11.69 Cr |
| Other Income | ₹1.08 Lakh | ₹2.12 Lakh | ₹24,000 | ₹0 | ₹48,000 | ₹0 | ₹95,700 | ₹100 |
| Total Income | ₹37.9 Cr | ₹16.99 Cr | ₹10.28 Cr | ₹13.61 Cr | ₹10.4 Cr | ₹10.8 Cr | ₹12.37 Cr | ₹11.69 Cr |
| Cost of Materials Consumed | ₹35.07 Cr | ₹14.38 Cr | ₹7.76 Cr | ₹10.81 Cr | ₹8.65 Cr | ₹6.72 Cr | ₹11.77 Cr | ₹8.67 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹95.28 Lakh | ₹77,000 | -₹4.51 Lakh | ₹60.64 Lakh | -₹74.49 Lakh | ₹1.42 Cr | -₹1.61 Cr | ₹35.16 Lakh |
| Employee Benefit Expense | ₹1.75 Cr | ₹1.24 Cr | ₹1.09 Cr | ₹88.6 Lakh | ₹1.24 Cr | ₹1 Cr | ₹93.39 Lakh | ₹1.46 Cr |
| Finance Costs | ₹39.57 Lakh | ₹33.97 Lakh | ₹48.81 Lakh | ₹49 Lakh | ₹61.1 Lakh | ₹49.7 Lakh | ₹46.59 Lakh | ₹45.28 Lakh |
| Depreciation & Amortisation | ₹35.28 Lakh | ₹30.67 Lakh | ₹33.94 Lakh | ₹36.78 Lakh | ₹37.76 Lakh | ₹37.04 Lakh | ₹34.41 Lakh | ₹33.86 Lakh |
| Other Expenses | ₹53.24 Lakh | ₹41.65 Lakh | ₹36.68 Lakh | ₹28.55 Lakh | ₹20.54 Lakh | ₹25.26 Lakh | ₹40.63 Lakh | ₹38.11 Lakh |
| Total Expenses | ₹37.15 Cr | ₹16.69 Cr | ₹10.01 Cr | ₹13.45 Cr | ₹10.34 Cr | ₹10.27 Cr | ₹12.3 Cr | ₹11.65 Cr |
| Profit Before Exceptional Items & Tax | ₹74.76 Lakh | ₹29.62 Lakh | ₹27.13 Lakh | ₹15.85 Lakh | ₹5.8 Lakh | ₹52.69 Lakh | ₹6.58 Lakh | ₹4.08 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹74.76 Lakh | ₹29.62 Lakh | ₹27.13 Lakh | ₹15.85 Lakh | ₹5.8 Lakh | ₹52.69 Lakh | ₹6.58 Lakh | ₹4.08 Lakh |
| Total Tax Expense | ₹21.96 Lakh | ₹7.92 Lakh | ₹7.89 Lakh | ₹4.07 Lakh | ₹1.9 Lakh | ₹30.03 Lakh | ₹2.23 Lakh | ₹1.35 Lakh |
| Net Profit | ₹52.8 Lakh | ₹21.7 Lakh | ₹19.24 Lakh | ₹11.78 Lakh | ₹3.9 Lakh | ₹22.67 Lakh | ₹4.34 Lakh | ₹2.73 Lakh |
| attributable to Owners | ₹52.8 Lakh | ₹21.7 Lakh | ₹0 | - | - | ₹0 | ₹0 | - |
| attributable to NCI | ₹0 | ₹0 | ₹0 | - | - | ₹0 | ₹0 | - |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹52.8 Lakh | ₹21.7 Lakh | ₹19.24 Lakh | ₹11.78 Lakh | ₹3.9 Lakh | ₹22.67 Lakh | ₹4.34 Lakh | ₹2.73 Lakh |
| EBITDA (computed) | ₹1.5 Cr | ₹94.26 Lakh | ₹1.1 Cr | ₹1.02 Cr | ₹1.05 Cr | ₹1.39 Cr | ₹87.58 Lakh | ₹83.23 Lakh |
| Basic EPS | ₹0.47 | ₹0.16 | ₹0.31 | ₹0.12 | ₹0.04 | ₹0.23 | ₹0.04 | ₹0.03 |
| Diluted EPS | ₹0.47 | ₹0.16 | ₹0.31 | ₹0.12 | ₹0.04 | ₹0.23 | ₹0.04 | ₹0.03 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹75.85 Cr | ₹36.93 Cr | ₹43.26 Cr | ₹51.31 Cr | ₹58.96 Cr | ₹51.36 Cr | ₹51.34 Cr | ₹48.08 Cr |
| Other Income | ₹3.44 Lakh | ₹1.44 Lakh | ₹92,900 | ₹88,600 | ₹10.08 Lakh | ₹9.46 Lakh | ₹12.01 Lakh | ₹8.59 Lakh |
| Total Income | ₹75.88 Cr | ₹36.95 Cr | ₹43.27 Cr | ₹51.32 Cr | ₹59.06 Cr | ₹51.45 Cr | ₹51.46 Cr | ₹48.16 Cr |
| Cost of Materials Consumed | ₹64.5 Cr | ₹28.22 Cr | ₹33.71 Cr | ₹40.36 Cr | ₹44.41 Cr | ₹40.49 Cr | ₹42.06 Cr | ₹39.14 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹63.98 Lakh | -₹58.05 Lakh | -₹40.49 Lakh | ₹51.56 Lakh | -₹2.31 Cr | ₹1.69 Cr | ₹51.72 Lakh | ₹45.59 Lakh |
| Employee Benefit Expense | ₹4.9 Cr | ₹4.39 Cr | ₹4.95 Cr | ₹4.63 Cr | ₹4.89 Cr | ₹3.76 Cr | ₹3.51 Cr | ₹2.53 Cr |
| Finance Costs | ₹1.46 Cr | ₹1.72 Cr | ₹1.59 Cr | ₹1.62 Cr | ₹1.68 Cr | ₹1.42 Cr | ₹1.54 Cr | ₹1.59 Cr |
| Depreciation & Amortisation | ₹1.36 Cr | ₹1.42 Cr | ₹1.54 Cr | ₹1.6 Cr | ₹1.76 Cr | ₹1.37 Cr | ₹1.46 Cr | ₹1.71 Cr |
| Other Expenses | ₹1.58 Cr | ₹1.13 Cr | ₹1.33 Cr | ₹1.47 Cr | ₹6.37 Cr | ₹2.2 Cr | ₹1.91 Cr | ₹2.3 Cr |
| Total Expenses | ₹74.43 Cr | ₹36.31 Cr | ₹42.71 Cr | ₹50.2 Cr | ₹56.81 Cr | ₹50.92 Cr | ₹51 Cr | ₹47.72 Cr |
| Profit Before Exceptional Items & Tax | ₹1.45 Cr | ₹64.13 Lakh | ₹55.84 Lakh | ₹1.13 Cr | ₹2.25 Cr | ₹52.88 Lakh | ₹45.65 Lakh | ₹43.97 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹3.76 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹1.45 Cr | ₹64.13 Lakh | ₹55.84 Lakh | ₹1.13 Cr | ₹2.25 Cr | ₹4.29 Cr | ₹45.65 Lakh | ₹43.97 Lakh |
| Total Tax Expense | ₹41.12 Lakh | ₹34.56 Lakh | ₹13.9 Lakh | ₹23.34 Lakh | ₹65.37 Lakh | ₹1.01 Cr | ₹12.82 Lakh | ₹3.28 Lakh |
| Net Profit | ₹1.04 Cr | ₹29.57 Lakh | ₹41.94 Lakh | ₹89.22 Lakh | ₹1.59 Cr | ₹3.28 Cr | ₹32.83 Lakh | ₹40.69 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹1.04 Cr | ₹29.57 Lakh | ₹41.94 Lakh | ₹89.22 Lakh | ₹1.59 Cr | ₹3.28 Cr | ₹32.83 Lakh | ₹40.69 Lakh |
| EBITDA (computed) | ₹4.26 Cr | ₹3.78 Cr | ₹3.69 Cr | ₹4.35 Cr | ₹5.69 Cr | ₹3.31 Cr | ₹3.46 Cr | ₹3.74 Cr |
| Basic EPS | ₹0.93 | ₹0.30 | ₹0.42 | ₹0.96 | ₹1.82 | ₹3.75 | ₹0.38 | ₹0.52 |
| Diluted EPS | ₹0.93 | ₹0.30 | ₹0.42 | ₹0.96 | ₹1.82 | ₹3.75 | ₹0.38 | ₹0.52 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹71.85 Cr | ₹58.58 Cr | ₹56.3 Cr | ₹56.63 Cr | ₹56.45 Cr | ₹49.88 Cr | ₹58.02 Cr | ₹82.77 Cr |
| Non-current Assets | ₹22.38 Cr | ₹25.16 Cr | ₹14.92 Cr | ₹15.23 Cr | ₹14.55 Cr | ₹13.87 Cr | ₹12.45 Cr | ₹13.03 Cr |
| Current Assets | ₹49.47 Cr | ₹33.42 Cr | ₹41.38 Cr | ₹41.4 Cr | ₹41.89 Cr | ₹36.01 Cr | ₹45.56 Cr | ₹69.74 Cr |
| Property, Plant & Equipment | ₹10.91 Cr | ₹11.54 Cr | ₹10.99 Cr | ₹12.22 Cr | ₹13.33 Cr | ₹13.19 Cr | ₹9.74 Cr | ₹11.06 Cr |
| Inventories | ₹18.35 Cr | ₹19.13 Cr | ₹18.5 Cr | ₹17.5 Cr | ₹17.49 Cr | ₹11.87 Cr | ₹16.43 Cr | ₹18.64 Cr |
| Trade Receivables | ₹28.13 Cr | ₹12.67 Cr | ₹21.07 Cr | ₹16.35 Cr | ₹22.86 Cr | ₹20.73 Cr | ₹25.45 Cr | ₹48.43 Cr |
| Cash & Equivalents | ₹27.1 Lakh | ₹11.54 Lakh | ₹13.71 Lakh | ₹7.53 Lakh | ₹4.44 Lakh | ₹3.55 Lakh | ₹1.21 Lakh | ₹15.89 Lakh |
| Equity (Net Worth) | ₹48.51 Cr | ₹34.11 Cr | ₹33.82 Cr | ₹31.7 Cr | ₹28.36 Cr | ₹26.77 Cr | ₹23.48 Cr | ₹23.16 Cr |
| Equity Share Capital | ₹13.18 Cr | ₹10 Cr | ₹10 Cr | ₹9.32 Cr | ₹8.74 Cr | ₹8.74 Cr | ₹8.74 Cr | ₹7.86 Cr |
| Borrowings (Non-current) | ₹1.81 Cr | ₹1.31 Cr | ₹2.67 Lakh | ₹1.02 Cr | ₹2.48 Cr | ₹60.3 Lakh | ₹87.72 Lakh | ₹68.97 Lakh |
| Borrowings (Current) | ₹9.8 Cr | ₹13.55 Cr | ₹13.98 Cr | ₹13.78 Cr | ₹13.95 Cr | ₹12.37 Cr | ₹8.69 Cr | ₹9.14 Cr |
| Total Debt (computed) | ₹11.61 Cr | ₹14.86 Cr | ₹14.01 Cr | ₹14.8 Cr | ₹16.43 Cr | ₹12.97 Cr | ₹9.57 Cr | ₹9.83 Cr |
| Current Liabilities | ₹18.02 Cr | ₹19.62 Cr | ₹19.44 Cr | ₹20.9 Cr | ₹22.86 Cr | ₹19.38 Cr | ₹30.98 Cr | ₹56.08 Cr |
| Total Liabilities | ₹23.34 Cr | ₹24.47 Cr | ₹22.48 Cr | ₹24.93 Cr | ₹28.08 Cr | ₹23.12 Cr | ₹34.53 Cr | ₹59.61 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹7.37 Cr | ₹3.16 Cr | ₹1.96 Cr | ₹2.24 Cr | ₹77.42 Lakh |
| Investing Cash Flow | -₹1.13 Cr | -₹2.32 Cr | -₹1.21 Cr | -₹2.27 Cr | -₹2.44 Cr |
| Financing Cash Flow | ₹8.65 Cr | -₹86.65 Lakh | -₹68.94 Lakh | ₹5.16 Lakh | ₹1.68 Cr |
| Capital Expenditure | ₹1.17 Cr | ₹2.33 Cr | ₹1.02 Cr | ₹85.66 Lakh | ₹2.46 Cr |
| Free Cash Flow (computed) | -₹8.53 Cr | ₹83.05 Lakh | ₹94.19 Lakh | ₹1.39 Cr | -₹1.68 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹15.56 Lakh | -₹2.16 Lakh | ₹6.19 Lakh | ₹3.08 Lakh | ₹89,400 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹35.55 Cr | ₹16.84 Cr | ₹23.46 Cr | ₹13.38 Cr | ₹79.4 Lakh | ₹10.77 Cr | ₹11.84 Cr | ₹6.35 Cr |
| Other Income | ₹1.08 Lakh | ₹2.12 Lakh | ₹24,000 | ₹0 | ₹48,000 | ₹0 | ₹95,700 | ₹100 |
| Total Income | ₹35.56 Cr | ₹16.86 Cr | ₹23.46 Cr | ₹13.38 Cr | ₹79.88 Lakh | ₹10.77 Cr | ₹11.85 Cr | ₹6.35 Cr |
| Cost of Materials Consumed | ₹31.81 Cr | ₹14.33 Cr | ₹18.49 Cr | ₹10.69 Cr | ₹6.04 Cr | ₹8.51 Cr | ₹9.79 Cr | ₹3.88 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹7.08 Lakh | ₹77,000 | ₹56.13 Lakh | ₹60.64 Lakh | -₹74.49 Lakh | -₹22.76 Lakh | ₹4.03 Lakh | ₹35.16 Lakh |
| Employee Benefit Expense | ₹1.73 Cr | ₹1.22 Cr | ₹1.95 Cr | ₹87.11 Lakh | ₹1.53 Cr | ₹94.51 Lakh | ₹86.12 Lakh | ₹1.05 Cr |
| Finance Costs | ₹34.46 Lakh | ₹29.6 Lakh | ₹81.85 Lakh | ₹41.99 Lakh | ₹53.48 Lakh | ₹42.58 Lakh | ₹38.75 Lakh | ₹37.03 Lakh |
| Depreciation & Amortisation | ₹35.05 Lakh | ₹30.44 Lakh | ₹70.24 Lakh | ₹36.55 Lakh | ₹37.45 Lakh | ₹36.72 Lakh | ₹34.09 Lakh | ₹33.54 Lakh |
| Other Expenses | ₹52.85 Lakh | ₹40.61 Lakh | ₹64.61 Lakh | ₹27.94 Lakh | ₹20.64 Lakh | ₹23.21 Lakh | ₹35.65 Lakh | ₹33.83 Lakh |
| Total Expenses | ₹34.83 Cr | ₹16.57 Cr | ₹23.17 Cr | ₹13.23 Cr | ₹7.95 Cr | ₹10.25 Cr | ₹11.78 Cr | ₹6.33 Cr |
| Profit Before Exceptional Items & Tax | ₹73.46 Lakh | ₹29.28 Lakh | ₹28.62 Lakh | ₹15.2 Lakh | -₹7.15 Cr | ₹52.07 Lakh | ₹7.37 Lakh | ₹2.64 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹73.46 Lakh | ₹29.28 Lakh | ₹28.62 Lakh | ₹15.2 Lakh | -₹7.15 Cr | ₹52.07 Lakh | ₹7.37 Lakh | ₹2.64 Lakh |
| Total Tax Expense | ₹21.79 Lakh | ₹7.76 Lakh | ₹8.07 Lakh | ₹4.06 Lakh | ₹1.26 Lakh | ₹29.87 Lakh | ₹1.96 Lakh | ₹1.47 Lakh |
| Net Profit | ₹51.67 Lakh | ₹21.52 Lakh | ₹20.55 Lakh | ₹11.14 Lakh | -₹7.16 Cr | ₹22.19 Lakh | ₹5.42 Lakh | ₹1.17 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹51.67 Lakh | ₹21.52 Lakh | ₹20.55 Lakh | ₹11.14 Lakh | -₹7.16 Cr | ₹22.19 Lakh | ₹5.42 Lakh | ₹1.17 Lakh |
| EBITDA (computed) | ₹1.43 Cr | ₹89.32 Lakh | ₹1.81 Cr | ₹93.74 Lakh | -₹6.24 Cr | ₹1.31 Cr | ₹80.21 Lakh | ₹73.21 Lakh |
| Basic EPS | ₹0.46 | ₹0.16 | ₹0.21 | ₹0.11 | ₹0.08 | ₹0.22 | ₹0.05 | ₹0.01 |
| Diluted EPS | ₹0.46 | ₹0.16 | ₹0.21 | ₹0.11 | ₹0.08 | ₹0.22 | ₹0.05 | ₹0.01 |
Shareholding Pattern of Concord Drugs Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 54.39%, retail and other public shareholders hold 45.61% of Concord Drugs Limited. The company had 4,464 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% |
| Public | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 54.39% | 54.39% | 55.41% |
| Public | 45.61% | 45.61% | 44.59% |
| Promoter change (YoY, %pts) | +0.00 | -1.02 | - |
Group Structure of Concord Drugs Limited
Concord Drugs Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Concord Drugs Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Proton Remedies Private Limited | U24232TG2008PTC061073 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Concord Drugs Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Dec 2011 | State Bank of India | ₹18.25 Cr | Open |
| 11 Mar 2022 | Others | ₹5 Cr | Satisfied |
| 10 Nov 2005 | Punjab National Bank | ₹1.4 Cr | Satisfied |
| 01 Jan 1998 | Small Industries Development Bank of India | ₹50 Lakh | Satisfied |
| 17 Oct 1997 | Small Industries Development Bank of India | ₹50 Lakh | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Concord Drugs Limited
Concord Drugs Limited has a workforce of 20 employees as of Mar 29, 2025.
Employee Count & EPFO Data of Concord Drugs Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Concord Drugs Limited
GSTIN & GST Filing Data of Concord Drugs Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Concord Drugs Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Concord Drugs Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Concord Drugs Limited
MSME Payment Delays by Concord Drugs Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Concord Drugs Limited
Subsidiaries & Group Companies of Concord Drugs Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Concord Drugs Limited with ownership details.
MCA Filings & Documents of Concord Drugs Limited
MCA Filings & Documents of Concord Drugs Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Concord Drugs Limited
Frequently Asked Questions about Concord Drugs Limited
Concord Drugs Limited is an active public limited company in the pharma sector based in Na, Telangana, India. It was incorporated on 24 April 1995 (31+ years old) and is registered under CIN L24230TG1995PLC020093. Listed on BSE: 538965. The company has 20 employees.
Concord Drugs Limited reported revenue of ₹45.26 Cr for FY 2025 (up 1.00% YoY).
The current directors of Concord Drugs Limited are:
The primary industry of Concord Drugs Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Concord Drugs Limited is listed on BSE with code 538965.
Concord Drugs Limited can be reached at the registered office: Survey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India, or through the website concorddrugs.in.